By Drugs.com
Report updated Apr 17, 2026
Drugs.com Medication Guide
For patients, caregivers, and healthcare professionals seeking reliable, peer-reviewed medication information and management tools.
Drugs.com Medication Guide is a well-regarded medical app that is free with in-app purchases. With a 4.8/5 rating from 50.3K reviews, it maintains solid user satisfaction. Users particularly appreciate medication management & information, though monetization & pricing remains a common concern.
What is Drugs.com Medication Guide?
Current Momentum
v3.1 · 4w ago
MaintenanceDrugs.com Medication Guide is currently in maintenance mode, focusing on incremental refinements to printing and UI animations. No major feature updates have been released in the last four months.
Active Nemesis
epocrates: Drug Info & Pill ID
By Epocrates
Other Rivals
7-Day Rank Pulse 🇺🇸
MedicalNo ranking data
Rating Pulse 🇺🇸
Recent User MoodAI-powered deep analysis surfacing high-signal insights. Still in beta, accuracy improves daily. For informational purposes only.
What makes this app unique?
What Does It Look Like?
How Is The App's Momentum Right Now?
Loading...
What Are The Key Features?
Searchable database of over 14,000 medications by imprint, color, and shape.
Locates lowest medication prices and nearby pharmacies to assist with cost management.
Access to FDA monographs and clinical data tailored for healthcare professionals.
Personalized health profile to track medications and interactions with offline access.
How much does it cost?
- Free: Core medication info with ads
- Plus Plan ($8.99/mo): Ad-removal and unlimited accounts
The app is shifting from a primarily ad-supported model to a high-priced subscription ($8.99/mo), which has triggered a sharp decline in user sentiment and 'greedy' brand associations.
Who Built It?
Drugs.com
Providing peer-reviewed medication information and identification tools to help patients and healthcare professionals manage drug safety.
Portfolio
2
Apps
Who is Drugs.com?
Drugs.com leverages its established web-based authority and proprietary drug database to maintain a dominant position in the mobile medical reference space. Their moat is built on institutional trust and massive search-driven distribution, allowing them to bridge the gap between professional clinical data and consumer utility. A key strategic signal is the recent shift toward more aggressive monetization, particularly high-friction weekly subscriptions in their utility apps, which tests the limits of brand loyalty against specialized competitors.
Who is Drugs.com for?
- Patients
- Caregivers
- Healthcare professionals requiring verified medication data
- Interaction checks
Portfolio momentum
Maintained an active development cycle with 9 updates across both apps in the last 6 months, including a major release within the last 8 days.
What other apps does Drugs.com make?
What do users think recently?
High confidence · Latest 100 of 50.1K total reviews analyzed
How did the latest release land?
What is the recent mood?
Recent user voice shows a excited sentiment. Users appreciate medication management & information and pill identification, but report monetization & pricing and technical issues & access.
What Users Love
What Frustrates Users
What is the competitive landscape for Drugs.com Medication Guide?
How's The Medical Market?
How does it evolve in the Medical market?
| Country | Category | Chart | Rank | Change |
|---|---|---|---|---|
| 🇵🇭 Philippines | Medical | AndroidFree | #97 | ▼21 |
| 🇸🇳 Senegal | Medical | AndroidFree | #120 | ▲6 |
The rivals identified
The Nemesis
Head to Head
While Drugs.com leads in consumer accessibility and price transparency, Epocrates maintains the edge in professional trust and clinical utility. Drugs.com faces a challenge with its declining sentiment trend compared to the stable professional reception of Epocrates.
What sets Drugs.com Medication Guide apart
Stronger focus on consumer-facing price comparison and pharmacy discount tools
More accessible language for patients and non-professional caregivers
What's epocrates: Drug Info & Pill ID's Edge
Higher overall rating volume and established professional authority
More frequent updates to clinical guidelines and drug monographs
Contenders
Superior pharmacy network and deeper discounts on prescriptions
Integrated telehealth services and mail-order pharmacy options
Medscape
★3.7 (63.9K)WebMD
⚡A massive medical reference platform that includes a robust drug database and interaction checker used by millions of professionals.
Includes a broader range of medical news, disease reference, and CME credits
Completely free access to a massive database of clinical information
WebMD: Symptom Checker
★4.7 (133.9K)WebMD
🚀The most recognized consumer health brand, offering overlapping tools like a pill identifier and interaction checker.
Broader focus on symptom checking and general health conditions
Highly optimized for general consumer search and discovery
Peers
SingleCare Rx Pharmacy Coupons
★4.8 (25.6K)SingleCare
⚡Competes directly with the medication savings and pharmacy locator features of Drugs.com.
Focuses exclusively on the financial aspect of medication management
Offers a loyalty program for additional savings on refills
Mayo Clinic
★3.6 (12K)Mayo Clinic
🚀A high-authority health information app that users often use to cross-reference drug side effects and treatments.
Content authored by world-renowned medical experts
Focuses on the patient-provider relationship and appointment management
New Kids on the Block
Uses AI-powered camera scanning for instant pill counting
Highly focused utility that solves a specific pain point for patients with complex regimens
The outtake for Drugs.com Medication Guide
Strengths to defend, gaps to attack
Core Strengths
- Massive database of 24,000+ peer-reviewed medications
- Highly-rated visual Pill Identifier tool
- Strong consumer brand trust (25M monthly visitors)
- Integrated pharmacy discount/pricing tools
Critical Frictions
- Aggressive $8.99/mo subscription pricing causing user friction
- Technical bugs in v3.1.51 (login failures, UI duplication)
- Manual entry for pill ID vs emerging AI camera scanning
Growth Levers
- Implement AI image search for pill identification to match PillEye
- Develop robust offline mode for users in low-connectivity areas
- Introduce tiered pricing to mitigate 'all-or-nothing' subscription backlash
Market Threats
- Epocrates' dominance in professional clinical trust
- Medscape's free access to clinical data attracting professional users
- GoodRx's superior pharmacy network and brand recognition
What are the next best moves?
Re-evaluate 'Plus Plan' pricing and feature gating.
High-frequency complaints indicate users feel 'erased' and priced out by the $8.99/mo tier, posing a major churn risk.
Hotfix login and UI duplication bugs in v3.1.51.
Medium-frequency complaints specifically cite inability to sign in and medications showing twice after the latest update.
Roadmap AI-powered camera scanning for Pill Identification.
User feedback explicitly requested an AI image search tool, and competitor PillEye is already utilizing computer vision for this purpose.
Feature Gaps vs Competitors
- AI-powered camera scanning (available in PillEye)
- Medical calculators and risk assessment tools (available in Epocrates)
- Telehealth services and mail-order options (available in GoodRx)
- CME credits for professionals (available in Medscape)
Key Takeaways
Drugs.com is a consumer powerhouse currently jeopardizing its user loyalty through an aggressive and poorly received monetization pivot. While its core utility in pill identification and interaction checking remains a major strength, the PM must urgently address the $8.99/mo price friction and technical stability issues to prevent a mass exodus to free alternatives like Medscape.
Where Is It Heading?
Declining
Frustrated user base regarding the $8.99/mo subscription shift — high risk of churn to free competitors.
Technical regressions in v3.1.51 (Mar 2026) causing login failures and UI bugs.
Active feature investment in UI customization and dark mode (Mar 2026) shows the app is not in maintenance mode.